A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis.
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Natalizumab (Primary) ; Keyhole limpet haemocyanin; Tetanus toxoid
- Indications Multiple sclerosis; Tetanus
- Focus Pharmacodynamics
- Sponsors Biogen
- 31 Aug 2018 Biomarkers information updated
- 14 Apr 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology.
- 28 Oct 2010 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History